To evaluate the clinical relevance of METTL1 and WDR4 in patients with BC, we performed IHC analysis of the METTL1 and WDR4 proteins with TMAs, quantifying the positive staining of tumor cells. This evidence concerns the gene WDR4 and neoplasm.